S-1 & Oxaliplatin

DRUG3 trials

Sponsors

Samsung Medical Center, The First Affiliated Hospital with Nanjing Medical University, Fudan University

Conditions

Colorectal CancerGastric AdenocarcinomaGastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

RecruitingNCT07464756

The First Affiliated Hospital with Nanjing Medical UniversityGastric Adenocarcinoma

Start: 2026-04-03End: 2030-07-31Target: 80Updated: 2026-07-16

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

RecruitingNCT07492615

Fudan UniversityGastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start: 2026-01-29End: 2033-02-20Target: 276Updated: 2026-03-25

Phase 3

Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer

CompletedNCT00677443

Samsung Medical CenterColorectal Cancer

Start: 2008-06-30End: 2011-01-31Updated: 2013-06-14

Related Papers

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.

2014-11-2615 citations

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial.

Journal of Clinical Oncology2014-05-202 citations

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.

2012-10-1098 citations